Efficacy and Safety of Azacitidine Combined With Interferon in the Treatment of Post-transplant Recurrence
Status:
Recruiting
Trial end date:
2022-08-28
Target enrollment:
Participant gender:
Summary
This study is a single-center, one-arm, prospective, phase II clinical trial with the primary
objective of assessing the effectiveness of azacitidine combined with interferon in the
prevention of recurrence after allogeneic transplantation of myeloid tumors (AML/MDS/MPN) in
the blood system. Sex and safety.
At the screening/baseline period, informed consent is obtained and the inclusion/exclusion
criteria are checked. Plan to enroll 30 patients, and collect demographic data, medical
history data, vital signs, physical examination, laboratory tests (hematuria, liver and
kidney function; immune indicators: T cell subsets, Treg, etc.), pregnancy test for female
patients And other necessary auxiliary inspections.
The time to start treatment is: a decrease in chimerism and/or minimal residual disease (MRD)
after myeloid tumor allogeneic hematopoietic stem cell transplantation.
Phase:
N/A
Details
Lead Sponsor:
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine